Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease

Authors not listed

Shanghai Greenvalley Pharmaceutical Co., Ltd. · 2011

Abstract

The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2011). Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease. <em>Shanghai Greenvalley Pharmaceutical Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT01453569
Vancouver
Anonymous. Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease. Shanghai Greenvalley Pharmaceutical Co., Ltd.. 2011.
BibTeX
@misc{anon2011PhaseI, title = {Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease}, author = {Anonymous}, journal = {Shanghai Greenvalley Pharmaceutical Co., Ltd.}, year = {2011}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings